Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics recruits first patients to its phase III birch trial

The year-long study over 50 sites in Germany, Sweden, Austria and Poland
Allergy Therapeutics recruits first patients to its phase III birch trial
The study could pave the way to a new short-course treatment

Allergy Therapeutics plc (LON:AGY) has recruited the first patients to its phase III trial of people with a sensitivity to birch pollen.

The year-long study over 50 sites in Germany, Sweden, Austria and Poland will recruit 550 patients and assess the efficacy and safety of its ultra-short course treatment Pollinex Quattro.

A successful outcome will pave the way to marketing authorisation in 2019.

"The start of our phase III trial investigating Pollinex Quattro Birch marks the beginning of a number of trials aimed at strengthening our product portfolio across Europe and helping the 6% of Europeans who test positive to birch allergens,” said chief executive Manuel Llobet.

If approved, Pollinex Quattro Birch will be the first MPL enhanced ultra-short course aluminium-free vaccine ever approved.

MPL, or monophosphoryl lipid A, is what’s called an adjuvant that enhances the body’s immune response.

“Combined with our clinical programme in the US focusing on Pollinex Quattro Grass, we aim to have a comprehensive global modified allergen + MCT and MPL vaccine package that focuses on delivering convenience, safety, efficacy and enhanced patient compliance," said Llobet.

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
consumer health segment overview
September 16 2018
The company sells clinically validated anti-ageing products for hair, skin and body.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use